Multidrug- and extensively drug-resistant TB in persons living with HIV

Expert Review of Respiratory Medicine

Volumn 3, Issue 3, 2009, Pages 245-254

  Matteelli, Alberto ^a   Richardson, Morgan D'Arcy ^b   Sotgiu, Giovanni ^c   Centis, Rosella ^d   Migliori, Giovanni Battista ^d  

^a UNIVERSITY OF BRESCIA   (Italy)

^b PATH   (United States)

^c UNIVERSITY OF SASSARI   (Italy)

^d IRCCS   (Italy)

Author keywords

Biomolecular epidemiology; HIV infection; Microbiological diagnosis; Treatment efficacy; XDR TB

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BONE MARROW SUPPRESSION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; EARLY DIAGNOSIS; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENOTYPE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PUBLIC HEALTH; SPUTUM CULTURE; SURVIVAL RATE; SURVIVAL TIME; TUBERCULOSIS CONTROL;

EID: 69949188331     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.15     Document Type: Article

References (67)

1. Andrews JR, Gandhi NR, Moodley P et al. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J. Infect. Dis. 198, 1582-1589 (2008).
2. Gandhi NR, Moll A, Sturm AW et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
3. Matteelli A, Migliori GB, Cirillo D et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev. Anti Infect. Ther. 5, 857-871 (2008).
4. Chen-Yuan C, Enarson DA, Fujiwara PI et al. Strategies of extensively drug resistance TB risk management for health workers and other care givers. Expert Rev. Resp. Med 2, 47-54 (2008).
5. Grimaldo ER, Tupasi TE, Rivera AB et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant M. tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Intern. J. Tuberc. Lung. Dis. 5, 546-550 (2001).
6. Kruuner A, Pehme L, Ghebremichael S et al. Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 35,146-155 (2002).
7. Sotgiu G, Ferrara G, Matteelli S et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur. Respir. J. 33(4), 871-881 (2009).
8. Gurumurthy P, Ramachandran G, Hemanth Kumar AK et al. Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob. Agents Chemother. 48, 4473-4475 (2004).
9. Peloquin CA, Nitta AT, Burman WJ et al. Low antituberculosis drug concentrations in patients with AIDS. Ann. Pharmacother. 30(9), 919-925 (1996).
10. Sahai J, Gallicano K, Swick L et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann. Intern. Med. 127(4), 289-293 (1997).
11. Perlman DC, Segal Y, Rosenkranz S et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin. Infect. Dis. 41(11), 1638-1647 (2005).
12. Swaminathan S, Narendran G, Venkatesan P et al. Aquired rifampicin resistance in HIV infected and uninfected patients with TB treated with a thrice-weekly short-course regimen. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
13. Reid A, Scano F, Getahun H et al. Towards universal access to HIV prevention, treatment, care, and support: the role of TB/HIV collaboration. Lancet Infect. Dis. 6, 483-495 (2006).
14. Horsburgh CJ Jr. Primary transmission of multidrug-resistant and extensively drug-resistant tuberculosis among HIV infected persons: what does the future hold in store? J. Infect. Dis. 198, 1577-1578 (2008).
15. Small PM, Shafer RW, Hopewell PC et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 328(16), 1137-1144 (2006).
16. Sonnenberg P, Murray J, Glynn JR et al. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 358(9294), 1687-1693 (2001).
17. Wells CD, Cegielski JP, Nelson LJ et al. HIV infection and multidrug-resistant tuberculosis - the perfect storm. J. Infect. Dis. 196, S86-S107 (2007).
18. Andrews J, Shah N, Gandhi N et al. Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J. Infect. Dis. 196, S482-S490 (2007).
19. Morozova I, Riekstina V, Sture G et al. Impact of the growing HIV-1 epidemic on multidrug-resistant tuberculosis control in Latvia. Int. J. Tuberc. Lung Dis. 7, 903-906 (2003).
20. WHO. WHO anti-tuberculosis drug resistance in the world - Fourth Global Report. WHO/HTM/TB/2008.394 WHO, Geneva, Switzerland (2008).
21. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2008 Report on the global AIDS epidemic. UNAIDS, Geneva, Switzerland (2008).
22. WHO. HIV/AIDS programme: towards universal access 2010. WHO, Geneva, Switzerland (2006).
23. Johansen IS, Thomsen VO, Marjamaki M et al. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy. Diagn. Microbiol. Infect. Dis. 50(2), 103-107 (2004).
24. Rusch-Gerdes S, Pfyffer GE, Casal M et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J. Clin. Microbiol. 44, 688-692 (2006).
25. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc. Lung Dis. 79, 3-29 (1998).
26. Hazbon MH, Brimacombe M, Bobadilla del Valle M et al. Population genetics study of isoniazid resistance mutations and evolution of multidrugresistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50, 2640-2649 (2006).
27. Morgan M, Kalantri S, Flore L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 5, 62-70 (2005).
28. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDR-plus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J. Clin. Microbiol. 45, 2635-2640 (2007).
29. Miotto P, Piana F, Cirillo DM et al. Genotype MTBDRplus: a further step toward rapid identification of drug-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 6, 393-394 (2008).
30. Barnard M, Albert H, Coetzee G et al. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 177, 787-792 (2008).
31. Ling DL, Zwerling AA, Pai M. Genotype MTBDR assays for the diagnosis of multi-drug resistant tuberculosis: a meta analysis. Eur. Respir. J. 32, 1165-1174 (2008).
32. Ginsburg AS, Grosset JH, Blshai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3, 432-442 (2003).
33. Giannoni F, Iona E, Sementilli F et al. Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49, 2928-2933 (2005).
34. WHO. Guidelines for the programmatic management of drug resistant tuberculosis. WHO, Geneva, Switzerland (2006).
35. Gandhi N, Shah S, Andrews J et al. High early mortality among HIV-infected patients with extensively drug-resistant or multidrug-resistant TB in rural South Africa. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
36. Migliori GB, Ortmann J, Girardi E et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg. Infect. Dis. 13, 780-782 (2007).
37. Migliori GB, Besozzi G, Girardi E et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur. Respir. J. 30, 623-626 (2007).
38. Kim HR, Hwang SS, Kim HJ et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin. Infect. Dis. 45, 1290-1295 (2007).
39. Migliori GB, Lange C, Girardi E et al. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin. Infect. Dis. 46, 958-959 (2008).
40. Migliori GB, Lange C, Girardi E et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 31, 904-910 (2008).
41. Migliori GB, Lange C, Centis R et al. Resistance to second-line injectables and treatment outcomes in MDR and XDR-TB cases. Eur. Respir. J. 31, 1155-1159 (2008).
42. Mitnick CD, Shin SS, Seung KJ et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359, 563-574 (2008).
43. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N. Engl. J. Med. 359, 657-659 (2008).
44. Eker B, Ortmann J, Migliori GB et al. Multidrug- and extensively-drug resistant tuberculosis: a TBNET survey in Germany. Emerg. Infect. Dis. 14, 1700-1706 (2008).
45. Keshavjee S, Gelmanova IY, Farmer PE et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 372, 1403-1409 (2008).
46. Kwon YS, Kim YH, Suh GY et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis. 47, 496-502 (2008).
47. Lai CC, Tan CK, Huang YT et al. Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. Clin. Infect. Dis. 47, e57-e63 (2008).
48. Banerjee R, Allen J, Westenhouse J et al. Extensively drug-resistant tuberculosis in California, 1993-2006. Clin. Infect. Dis. 47, 450-457 (2008).
49. Bonilla CA, Crossa A, Jave HO et al. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS ONE 3, e2957 (2008).
50. Kim DH, Kim HJ, Park SK et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 178, 1075-1082 (2008).
51. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 2, 736-743 (2006).
52. McIlleron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect Dis. 196, S63-S75 (2007).
53. Colebunders R, John L, Huyst V et al. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int. J. Tuberc. Lung Dis. 10(9), 946-953 (2006).
54. WHO. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. WHO, Geneva, Switzerland (2006).
55. Abdool Karim S, Naidoo K, Grobler A et al. Initiating ART during TB treatment significantly increases survival: results of a randomised controlled clinical trial in TB/ HIV co-infected patients in South Africa. Presented at: 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, 8-11 February 2009.
56. Joseph P, Severe P, Ferdinand S et al. Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS 20, 415-418 (2006).
57. Bock NN, Jensen PA, Miller B, Nardell A. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J. Infect. Dis. 196, S108-S113 (2007).
58. WHO. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. WHO, Geneva, Switzerland (2006).
59. Park IN, Hong SB, Oh YM et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58(3), 701-704 (2006).
60. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases. J. Infect. 52(2), 92-96 (2006).
61. Fortún J, Martín-Dávila P, Navas E et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56(1), 180-185 (2005).
62. Migliori GB, Eker B, Richardson MD et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB. Eur. Respir. J. (2009) (Epub ahead of print).
63. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49(6), 2289-2293 (2005).
64. Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3(11), e466 (2006).
65. Tomioka H. Current status of some antituberculosis drugs and the development of new antituberculous agents with special reference to their in vitro and in vivo antimicrobial activities. Curr. Pharm. Des. 12(31), 4047-4070 (2006).
66. Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3(6), 323-324 (2007).
67. Protopopova M, Hanrahan C, Nikonenko B et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56(5), 968-974 (2005).